Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App





CDC Provides Test Protocol for Novel Coronavirus

By LabMedica International staff writers
Posted on 11 Feb 2020
The US Centers for Disease Control and Prevention (Atlanta GA, USA) has publicly posted its assay for novel coronavirus 2019-nCoV and is now developing the test into kits. More...
The CDC diagnostic test is a reverse transcriptase real-time PCR (rRT-PCR) assay developed for respiratory and blood serum samples. The protocol to make the assay has been made publicly available.

Specifically, if a person is identified with a travel history or contact that could have led to exposure, and also has a fever and respiratory illness, typically a health department is alerted. Through discussion with CDC, it is determined whether diagnostics are merited, and a sample is sent to CDC. All told 260 people in 26 states are currently or have been investigated for 2019-nCoV infection. To date, the agency has screened 2,400 people at five selected USA ports of entry. It is continuing to assess the public health situation as it evolves, she said, adding that CDC will likely be providing guidance on potential additional travel restrictions in the next few days.

The protocol specifies primers and probes, provides guidance on sample preparation, and advises performing rRT-PCR on the AB 7500 Fast DX thermal cycler (Thermo Fisher Scientific, Waltham, MA, USA). The agency's interim guidance for 2019-nCoV testing indicates biosafety precautions of using RNase Away or freshly prepared solution of 10% bleach for cleanup. In addition to the 11 cases confirmed positive in the USA using the rRT-PCR test, and167 cases confirmed negative, there are also 82 cases pending, which the agency said on its website includes specimens received and awaiting testing, as well as specimens en route to CDC.

Nancy Messonnier, MD, the director of the National Center for Immunization and Respiratory Diseases, said, “The time lag between the decision that a patient needs further laboratory testing and a test result is somewhere around a day, depending on geographically where that patient is being seen and how we can most efficiently ship. This is essentially a blueprint to make the test. Currently we are refining the use of this test so we can provide optimal guidance to states and laboratorians on how to use it.”

Related Links:
US Centers for Disease Control and Prevention
Thermo Fisher Scientific



Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
New
Automated Immunoassay Analyzer
SuperFlex™
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: WashU Medicine researchers found that dozens of blood proteins shift during Alzheimer’s treatment and may help monitor the effects of the medication. (Image Credit: Matt Miller/WashU Medicine)

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Molecular Diagnostics

view channel
Image: University of Florida scientists Hugh Fan, Ph.D., and John Lednicky, Ph.D., led the development of a cost-effective, accurate handheld device capable of simultaneously testing for seven different mosquito-borne viruses. (Image Credit: UF Health photo by Hannah Clark)

Portable Test Differentiates Seven Mosquito-Borne Viruses at Point of Care

Mosquito-borne viral illnesses can present with overlapping symptoms such as fever, joint pain, fatigue, and rash, making them difficult to distinguish without laboratory testing. In these settings, clinicians... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.